Researchers Identify Molecular Mechanism Behind Intervertebral Disc Degeneration
A recent study published in Nature Health Sciences uncovers how a specific regulatory protein drives cell damage in spinal disc degeneration and points to potential new treatments.
Key points
- USP14 enzyme levels are elevated in degenerative spinal disc tissues.
- Targeting USP14 helps restore protective autophagy and reduces cell damage.
- Preclinical testing in rat models showed that local delivery of IU-1 reduced disc degeneration.
A collaborative team of researchers has uncovered a specific molecular pathway that accelerates intervertebral disc degeneration, a widespread condition linked to nutrient deprivation in spinal tissues. Investigating human and rat degenerative tissues, the study revealed that an enzyme called deubiquitinase USP14 is amplified during cellular stress, leading to the breakdown of spinal disc cells and extracellular matrix.
According to the findings, USP14 stabilizes leucyl-tRNA synthetase, which in turn hyperactivates the mTORC1 signaling pathway and suppresses protective cellular autophagy. When the research team used genetic techniques or pharmacological inhibitors such as IU-1 to target USP14, they observed a restoration of autophagic activity and reduced cellular damage in laboratory models. Furthermore, delivering IU-1 directly into the intervertebral discs of rat models successfully mitigated the progression of degeneration.
While these preclinical findings offer promising insights into potential therapies for back pain and disc disease, experts note that the work is still in early laboratory and animal stages. Clinical applications in humans will require extensive further investigation and human trials. Readers experiencing chronic back pain or spinal conditions should consult a qualified physician before considering any experimental treatments.
What to know: Scientists discovered that blocking the USP14 enzyme can protect spinal disc cells from nutrient stress by restoring autophagy, offering a possible target for future treatments.
Source Nature Health Sciences — nature.com/articles/s41419-026-09377-7 ↗
Read next
🔬ResearchJAK Inhibitor Shows Potential in Managing Immune Dysregulation in Down Syndrome
A phase 2 clinical trial indicates that the medication tofacitinib can safely reduce chronic immune overactivity in individuals with Down syndrome, leading to improvement…
🏃FitnessUnderstanding and Addressing Love Handles Through Lifestyle Changes
Experts clarify that spot reduction of fat is not physiologically possible, recommending a combination of calorie management and high-intensity interval training instead.
🏃FitnessCiele Releases New Woolmark-Certified Merino Winter Running Apparel
Montreal-based brand Ciele has launched its second collection of merino wool running gear, featuring performance-focused fabrics designed for cold-weather training.
❤️Conditions & CareBlood-Based Genetic Signature May Predict CAR T-Cell Therapy Success in Lymphoma
Researchers have identified a specific RNA signature in blood plasma that may help predict how well lymphoma patients respond to CAR T-cell therapy.
🧠AI AnalysisUltraprocessed Diets May Impact Brain Reward Systems in Younger Adults
A Virginia Tech study suggests that individuals aged 18 to 21 may experience changes in brain reward processing after consuming ultraprocessed foods, a response not obser…
🧠Mind & Mental HealthAddressing Body Image and the Reality of Gluteal Anatomy
A personal reflection on the social and psychological impact of body shape, specifically regarding the gluteal region, and the limitations of consumer solutions for perce…